OMC
LCTX icon

Old Mission Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Old Mission Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-326,600
Closed -$284K – 523
2020
Q2 		$284K Buy
+326,600
New +$287K 0.02% 336
2019
Q2 		– Sell
-54,300
Closed -$71K – 304
2019
Q1 		$71K Buy
+54,300
New +$67.5K 0.01% 190

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Old Mission Capital's LCTX Position: Q3 2020 in Review

Old Mission Capital sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 326,600 shares — an estimated $284K sold.

Old Mission Capital first reported a position in LCTX in Q1 2019 and held it in 2 quarters. The position peaked at $284K in Q2 2020. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • Old Mission Capital reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Old Mission Capital sold 326,600 Lineage Cell Therapeutics shares in Q3 2020, an estimated $284K.
  • Old Mission Capital first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 2 quarters.
  • Old Mission Capital's Lineage Cell Therapeutics position peaked at $284K in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Old Mission Capital's 13F filing for Q3 2020, filed 16 Nov 2020.